Article

Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study.

Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia
PLoS ONE (Impact Factor: 3.53). 01/2013; 8(3):e59649. DOI: 10.1371/journal.pone.0059649
Source: PubMed

ABSTRACT Mild cognitive impairment (MCI) is associated with an increased risk of developing dementia. However, many individuals diagnosed with MCI are found to have reverted to normal cognition on follow-up. This study investigated factors predicting or associated with reversion from MCI to normal cognition.
Our analyses considered 223 participants (48.9% male) aged 71-89 years, drawn from the prospective, population-based Sydney Memory and Ageing Study. All were diagnosed with MCI at baseline and subsequently classified with either normal cognition or repeat diagnosis of MCI after two years (a further 11 participants who progressed from MCI to dementia were excluded). Associations with reversion were investigated for (1) baseline factors that included diagnostic features, personality, neuroimaging, sociodemographics, lifestyle, and physical and mental health; (2) longitudinal change in potentially modifiable factors.
There were 66 reverters to normal cognition and 157 non-reverters (stable MCI). Regression analyses identified diagnostic features as most predictive of prognosis, with reversion less likely in participants with multiple-domain MCI (p = 0.011), a moderately or severely impaired cognitive domain (p = 0.002 and p = 0.006), or an informant-based memory complaint (p = 0.031). Reversion was also less likely for participants with arthritis (p = 0.037), but more likely for participants with higher complex mental activity (p = 0.003), greater openness to experience (p = 0.041), better vision (p = 0.014), better smelling ability (p = 0.040), or larger combined volume of the left hippocampus and left amygdala (p<0.040). Reversion was also associated with a larger drop in diastolic blood pressure between baseline and follow-up (p = 0.026).
Numerous factors are associated with reversion from MCI to normal cognition. Assessing these factors could facilitate more accurate prognosis of individuals with MCI. Participation in cognitively enriching activities and efforts to lower blood pressure might promote reversion.

Download full-text

Full-text

Available from: Darren Lipnicki, Jul 05, 2015
1 Follower
 · 
232 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mild cognitive impairment (MCI) is associated with an increased risk of developing dementia. This is clinically relevant overt dementia can be prevented if treatment strategies are devised for MCI. Neuropsychological deficits in this condition are very common and are important clinically for treatment and outcomes. We aimed to review various neuropsychological deficits in MCI. Further, we have presented the current evidence for nosological status, neuroanatomical basis, and clinical outcome of this heterogeneous construct. All published papers on the topic of neuropsychological deficits in MCI on Medline and other databases were reviewed. A wide range of memory and executive function deficits are common in MCI patients. However, several studies are limited by either improper designs or inadequate sample sizes. Several neuropsychological impairments like memory function and executive functions can be diagnosed in MCI. The evidence base for the exact neuroanatomical basis of MCI is not robust yet. However, given the wide range of outcomes, controversies and debates exist regarding the nosological significance of the deficits. Hence, more studies are needed to specifically locate the impairments and further delineate the construct of MCI.
    Annals of Indian Academy of Neurology 03/2013; 16(3):310-318. DOI:10.4103/0972-2327.116907 · 0.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To determine acute effects of intranasal insulin on regional cerebral perfusion and cognition in older adults with type 2 diabetes.Research design and methodsThis was a proof-of-concept, randomized, double-blind, placebo-controlled intervention evaluating the effects of a single 40IU dose of insulin or saline on vasoreactivity and cognition in 15 diabetic and 14 control subjects. Measurements included regional perfusion, vasodilatation to hypercapnia at 3 Tesla MRI and neuropsychological evaluation.ResultsIntranasal insulin administration was well tolerated and did not affect systemic glucose levels. No serious adverse events were reported. Across all subjects, intranasal insulin improved visuospatial memory (p<0.05). In the diabetes group, an increase of perfusion after insulin administration was greater in the insular cortex as compared to the control group (p=0.0003). Cognitive performance following insulin administration was related to regional vasoreactivity. Improvements of visuospatial memory after insulin administration in the diabetes group (R(2)adj=0.44, p=0.0098) and of verbal fluency test in the control group (R(2)adj =0.64, p=0.0087) were correlated with vasodilatation in the middle cerebral artery territory.Conclusions Intranasal insulin administration appears safe and does not affect systemic glucose control, and may provide acute improvements of cognitive function in patients with type 2 diabetes, potentially through vasoreactivity mechanisms. Intranasal insulin-induced changes in cognitive function may be related to vasodilatation in the anterior brain regions, such as insular cortex that regulates attention-related task performance. Larger studies are warranted to identify long-term effects and predictors of positive cognitive response to intranasal insulin therapy.
    Diabetes care 10/2013; 37(3). DOI:10.2337/dc13-1672 · 8.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Non-demented community-dwelling older adults aged 70-90 years (n = 1,037) randomly recruited from the electoral roll completed neuropsychological and medical assessments over six years. The overall prevalence of mild cognitive impairment (MCI) at baseline was 36.7%. Risk factors for MCI include APOE ϵ4 allele carrier status, high homocysteine, heart disease, poor odour identification, low visual acuity and low mental activity, but notable age and sex differences were observed. Neuropsychiatric symptoms were rare; depression was the most common and was associated with cognitive impairment in at least one domain as well as subsequent dementia 2 years later. Poorer cognitively demanding functional abilities were associated with cognitive impairment. Biomarkers for cognitive impairment and decline were identified. Inflammatory markers and plasma apolipoprotein levels were associated with poorer performance in the attention/processing speed domain. Measures of white matter lesions, white matter integrity, sulcal morphology and tractography were identified as novel biomarkers of early cognitive decline. Stronger deactivation in the posteromedial cortex with increasing memory load on functional MRI predicted future decline. Compared to previous reports, our prevalence rates of MCI were higher but rates of progression to dementia and reversion to normal were similar, as were risk factors for progression to dementia.
    International Review of Psychiatry 12/2013; 25(6):711-25. DOI:10.3109/09540261.2013.860890 · 1.80 Impact Factor